Leadership

Toon Overstijns joined Miltenyi in 2017 and is member of the board of directors of Miltenyi Biotec and chairman of the Board of Miltenyi Biomedicine.

Before joining the company, Toon was more than 25 years at Janssen Pharmaceuticals (J&J) were he held different positions. He was responsible for managing the Global Infectious Diseases & Vaccines Therapeutic Area based in USA. Prior to that he was company president of Janssen Japan based in Tokyo and Managing Director Janssen Germany based in Neuss.

Toon served as Field Officer for UNICEF in Bangladesh and Ethiopia prior to joining the pharmaceutical industry.

Toon holds an MD degree as well as a Chemistry and MBA degree. He studied at the University of Leuven in Belgium, the University of Stellenbosch in South Africa and at Stanford University in California.

Norbert Hentschel joined Miltenyi in 2001 and is responsible for the global Finance, IT and Purchasing Organization.

He joined Miltenyi Biotec in 2001 from E.ON, where he served as an Expert in US Generally Accepted Accounting Principles. He started his Career in the Audit Division of Arthur Andersen, where he was involved in international IPOs, M&A Transactions, and year-end audits.

Norbert holds a Master’s degree in Economics (Dipl.-Volkswirt) from the University of Cologne. He has been a board member of the industry association BIO Deutschland since 2007, and he is co-editor of the Corporate Finance Magazine published by Handelsblatt Fachmedien.

Hans-Jürgen Fülle is a physician scientist with extensive experience in research and drug development in academia and the pharmaceutical industry. He joined Miltenyi Biomedicine in 2022 and oversees the Global Regulatory Affairs, Global Pharmacovigilance and Clinical QA functions.

Previously he held strategic roles in Novartis Global Drug Development Regulatory Affairs across all stages of global development of medicinal products, from early to confirmatory clinical development, registration and post-marketing in US, EU and other major regions. Most recently, he was responsible for the regulatory strategy of Zolgensma^® and multiple investigational AAV gene therapies in development at Novartis Gene Therapies. He also provided regulatory leadership for rare diseases programs, regenerative medicines and advanced therapy medicinal products in various therapeutic areas at the Novartis Institutes for BioMedical Research (NIBR).

Hans-Jürgen completed his medical training at FU Berlin and U Freiburg i. Br., Germany. He holds a Doctorate in Medicine (LMU Munich, Germany), a master’s degree in Biochemistry (FU Berlin, Germany) and a master’s degree in Regulatory Science (USC, Los Angeles, CA).

Tomasz Skrzypczak leads the global commercial organization, being responsible for strategy and organizational structure, expanding our presence worldwide in light of CAR-T therapies future launch, primarily Zamtocabtagene Autoleucel. He joined Miltenyi Biomedicine in 2023.

Tomek has more than 20 years of experience in commercial activities in the innovative pharmaceutical industry. His track record includes various Strategic and Operational functions (General Management, Marketing, Sales, Digital/CRM/BI) in several geographies, on both local and regional levels.

Tomek earned a Marketing and General Management degree at the Poznań University of Economics and Business.

Anna Wijatyk joined Miltenyi Biomedicine in 2021 and heads the Boston Biomedicine office. She is responsible for leading clinical development of our current and future pharmaceutical assets in the US, such as Zamtocabtagene. She provides strategic medical input into clinical development activities, including clinical oversight of regulatory communication and submissions. She will maintain close relationships and collaborate with medical experts in US.

Before joining the company, Anna was Vice President, Head of Clinical Development at Agenus Inc., where she was responsible for the checkpoint inhibitors pipeline and cancer vaccine programs. Before that, she was responsible for the global development of the oncology portfolio at Shire Pharmaceuticals.

Prior to her experience in the biotech industry in the Boston area, Anna had several medical leadership roles at Bristol Myers Squibb, Baxter, Boston Scientific and Parexel in the US.

Anna holds several pharmaceutical qualifications including a Medical Doctor degree.

Silke Holtkamp joined Miltenyi in 2009 and is leading the Clinical Development Department with all of the functions involved in Europe, which includes overseeing the Clinical Development strategy to support product approval with EMA as well as overseeing all clinical operational activities in Europe.

Silke has long-standing expertise in all aspects of clinical research, with medicinal products as well as medical devices, in a variety of companies. With more than 10 years of experience within the Miltenyi Group in different functions in Clinical Development, she has been successful in building, leading and re-structuring teams within this field.

Silke studied Biology and holds a Doctor of Natural Science (Dr.rer.nat) degree from Johannes Gutenberg University of Mainz, Germany.

Dr. Tobias Kampfenkel serves as Vice President of Early Clinical Research & Development and Translational Medicine at Miltenyi Biomedicine. In this global role, he oversees the clinical development of early-stage assets across solid tumors, autoimmune diseases and hematologic malignancies. His responsibilities include leading the clinical operations group and shaping the translational interface between preclinical research and clinical application.

Tobias brings a unique combination of academic rigor, clinical expertise, and strategic leadership to his role. He is a board-certified Internist, Hematologist, and Medical Oncologist with additional certifications in Palliative Care and Emergency Medicine. Prior to joining the pharmaceutical industry, he served as an attending physician at the University Hospitals of Bochum and Essen in Germany, focusing on both solid tumors and hematologic malignancies.

Before joining Miltenyi, Tobias held senior roles at Johnson & Johnson Innovative Medicine, where he led global development programs in hematology, including pivotal Phase 3 trials and worldwide regulatory submissions. His work contributed to the advancement of novel therapies in multiple myeloma and other blood cancers.

He studied medicine at Ruhr-University Bochum and Université Louis Pasteur in Strasbourg and holds a Master of Health Business Administration (MHBA) from the University of Erlangen-Nürnberg. His career reflects a commitment to translating scientific innovation into meaningful clinical advances for patients.

Linda Hanssens joined Miltenyi Biomedicine in 2019 and is responsible for developing and managing all research needed to translate the most promising projects from basic research into early clinical trials to demonstrate safety and a first proof of concept in healthy volunteers and/or patients.

As head of Medical Affairs Linda is responsible for developing the global medical strategy of the cell therapy portfolio, managing educational and scientific activities such as advisory boards and Investigator Initiated Trials (IITs) as well as supervising the Medical Science Liaisons (MSLs).

Linda has built solid experience in medical affairs and clinical development in several large pharmaceutical companies such as UCB, BMS and GSK.

Linda received her Doctorate in Medical Sciences and a postgraduate degree in Public Health Sciences from the University of Liege, Belgium. She holds a Master’s degree in Molecular Biology from the University of Louvain, Belgium.

Michael Terhoeven joined Miltenyi Biomedicine in 2020 and is responsible for implementing the Supply Chain Strategy, leading the CAR-T cell logistics and the contracting for our manufacturing globally.

Michael joined the company from DHL, where he had long long-standing career of 16 years with multiple strategic roles including life science logistics, cold chain and environment monitoring. Prior to DHL, he worked with a pre-clinical biotech start-up in Berlin and for 7 years with the Boston Consulting Group.

Michael holds a Doctor of Natural Sciences (Dr. rer. Nat.) in Mathematical Physics from the University of Bonn.